Search

2665 Results for "Cancer"

Biotech Company Settles With Family of Henrietta Lacks, Whose Cells Revolutionized Medicine

Henrietta Lacks’ cells were taken without her knowledge while she was a cancer patient more than 70 years ago and were the first to be successfully cloned. Cervical cells from Henrietta Lacks, a cancer patient who died more than 70 years ago, are a cornerstone of modern medicine, but her family has never been compensated...

Effective Treatments for Melanoma Brain Metastases

Melanoma brain metastasis (MBM) is found in 30–40% of patients with advanced melanoma. While treatment options are accessible, MBM remains a challenge to treat effectively. Around 30-40% of patients with advanced melanoma present with melanoma brain metastases (MBM) at diagnosis, with a higher percentage of patients exhibiting MBM at the time of death in autopsy....

Multiple Myeloma Treatment, Research, and Clinical Trials

In this MD Newsline exclusive interview with oncologist Dr. Onyemaechi Okolo, we discuss her treatment strategy for multiple myeloma. We also discuss the newest treatment for multiple myeloma and how to diversify cancer clinical trials. MD Newsline: What is your treatment strategy for multiple myeloma, and how is it tailored to each patient? How do these...

Improving the Transition to Adult Care in Sickle Cell Disease

The transition from pediatric to adult treatment programs poses a challenge in the management of sickle cell disease. Developing transition programs with better knowledge of the factors that lead to transition success will be vital to improving patient outcomes.   Patients with sickle cell disease require lifelong treatment Transitioning from pediatric to adult care is a...

Underrepresentation of Minorities in Lymphoma Trials

Staff Writer: Deileta Kamhunga It’s well established that there are serious inequities in cancer care and outcomes in the U.S. and around the globe. But are pivotal clinical trials including populations representative of all patients, particularly those who experience these inequities? Researchers set out to determine if clinical trials for lymphomas reflect the populations affected...

What Is the First Sign of Multiple Myeloma?

Multiple Myeloma is a type of cancer that impacts the plasma cells in the bone marrow. It is characterized by the proliferation and multiplication of these cells resulting in the production of antibodies that can potentially harm various systems within the body.  Diagnosing this cancer can be quite complex because its symptoms tend to manifest...

New Leadership Elected to American Society of Hematology

The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of three new members to its Executive Committee for terms beginning after the 2021 ASH Annual Meeting, December 11-14 in Atlanta, Georgia. Mohandas Narla, DSc, will serve a one-year term as...

Mortality Lowest With Five Servings of Fruit, Vegetables/Day

MONDAY, March 1, 2021 (HealthDay News) — Mortality is lowest with consumption of five servings of fruit and vegetables per day, according to a study published online March 1 in Circulation. Dong D. Wang, M.D., Sc.D., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues followed 66,719 women from the Nurses’...

Obesity vs. Morbid Obesity: Understanding the Difference

Obesity is a serious health condition that affects a significant portion of the population, leading to numerous health risks and complications. However, within the realm of obesity, there are different categories that vary in terms of severity and associated health risks. This article aims to clearly understand the difference between obesity and morbid obesity, including...

Outcomes of Nivolumab, Ipilimumab, and Sunitinib in Advanced Sarcomatoid RCC

Individuals with poor- or intermediate-risk advanced sarcomatoid renal cell carcinoma may benefit from better first-line treatment outcomes with nivolumab and ipilimumab than with sunitinib.  Patients suffering from advanced sarcomatoid renal cell carcinoma (sRCC) have poor prognostic outcomes and limited treatment options. The first-line treatment of sRCC comprises nivolumab with ipilimumab (NIVO+IPI), which has greater efficacy...
<< >>

Stay informed on the latest health disparities research, cultural sensitivity education, and how you can help improve patient outcomes.
This field is for validation purposes and should be left unchanged.